Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 13/20 | 0.42 |
| ▸ | FNTA | P49354 | 5/20 | 0.41 |
| ▸ | FNTB | P49356 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486396 | 0.87 | MELK (0.46) | MELKALDH1A1MAPTGAAPOLB | |
| SCHEMBL4478066 | 0.85 | MELK (0.45) | MELKFNTAFNTBALDH1A1MAPT | |
| SCHEMBL4466112 | 0.85 | MELK (0.43) | MELKFNTAFNTBALDH1A1MAPT | |
| SCHEMBL4488267 | 0.82 | MELK (0.44) | MELKFNTAFNTBALDH1A1MAPT | |
| SCHEMBL4471914 | 0.81 | MELK (0.46) | MELKFNTAFNTBALDH1A1MAPT | |
| SCHEMBL4471906 | 0.80 | MELK (0.51) | MELKFNTAFNTB | |
| SCHEMBL4476670 | 0.79 | FNTA (0.41) | MELKFNTAFNTBALDH1A1MAPT | |
| SCHEMBL4503875 | 0.78 | MELK (0.49) | MELKFNTAFNTBALDH1A1MAPT | |
| SCHEMBL4476383 | 0.78 | ALDH1A1 (0.44) | MELKFNTAFNTBALDH1A1MAPT | |
| SCHEMBL4483168 | 0.77 | MELK (0.51) | MELKFNTAFNTBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | MELK 3735/4885FNTA 900/4885FNTB 513/4885 |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PDE4B, PDE7B, PDE4A | MELK 3735/4885FNTA 900/4885FNTB 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.